Zymeworks Inc. (NYSE:ZYME - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Zymeworks in a note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.56) for the quarter, up from their prior estimate of ($0.59). The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks' Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.38) EPS.
ZYME has been the topic of several other reports. Citigroup increased their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. HC Wainwright lifted their price target on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Finally, Lifesci Capital started coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.00.
Check Out Our Latest Research Report on ZYME
Zymeworks Stock Performance
Zymeworks stock traded down $0.93 during mid-day trading on Thursday, hitting $11.92. 232,520 shares of the company traded hands, compared to its average volume of 589,307. The stock has a market cap of $829.36 million, a price-to-earnings ratio of -7.95 and a beta of 1.24. Zymeworks has a one year low of $8.21 and a one year high of $17.70. The stock has a fifty day moving average price of $11.99 and a 200-day moving average price of $13.50.
Insider Transactions at Zymeworks
In other news, Director Ecor1 Capital, Llc acquired 73,953 shares of the firm's stock in a transaction on Wednesday, April 16th. The stock was acquired at an average price of $11.16 per share, with a total value of $825,315.48. Following the completion of the purchase, the director now directly owns 17,773,727 shares in the company, valued at approximately $198,354,793.32. This trade represents a 0.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought a total of 1,350,347 shares of company stock worth $16,137,499 in the last ninety days. Insiders own 1.92% of the company's stock.
Hedge Funds Weigh In On Zymeworks
Institutional investors have recently modified their holdings of the stock. Blackstone Inc. raised its holdings in shares of Zymeworks by 2,171.4% in the fourth quarter. Blackstone Inc. now owns 569,715 shares of the company's stock valued at $8,341,000 after acquiring an additional 544,633 shares in the last quarter. Walleye Capital LLC purchased a new position in Zymeworks during the 4th quarter worth $6,629,000. Schroder Investment Management Group acquired a new position in Zymeworks during the 4th quarter valued at about $4,892,000. Assenagon Asset Management S.A. boosted its holdings in Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company's stock worth $9,403,000 after acquiring an additional 311,107 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Zymeworks by 565.8% during the fourth quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock valued at $4,833,000 after acquiring an additional 280,544 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Further Reading
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
